New Amsterdam Pharma
Danielle Curcio has a wealth of experience in the pharmaceutical industry. Danielle began their career in 2007 as a Regulatory Affairs Specialist at Givaudan. In the same year, they also began working at The Medicines Company as a Clinical Trials Associate and Clinical Trial Coordinator. From 2011 to 2015, they worked at Omthera Pharmaceuticals, Inc. as a Project Manager, Clinical Development. Danielle then moved to Regeneron Pharmaceuticals, Inc. in 2015 as a Clinical Trial Manager. In 2017, they returned to The Medicines Company as a Clinical Project Director. In 2020, they began working at Novartis as a Sr. Clinical Project Director and in 2021, they began working at NewAmsterdam Pharma as an Executive Director, Clinical Operations and a Senior Director, Clinical Operations.
Danielle Curcio completed their Master of Business Administration (MBA) in Management from Centenary University in 2012. Prior to that, they earned a BS in Biology and Chemistry from Sacred Heart University in 2007.
This person is not in any offices
New Amsterdam Pharma
1 followers
Founded in 2019 by the venture capital firm Forbion and John Kastelein, NewAmsterdam Pharma is a privately held, clinical-stage company focused on the research and development of transformative therapies for cardiometabolic diseases. Its mission is to improve patient care in populations where traditional therapies are not tolerated or have been unsuccessful.